These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Dynamic contrast-enhanced perfusion MR imaging with SPIO: a pilot study.
    Author: Amemiya S, Akahane M, Aoki S, Abe O, Kamada K, Saito N, Ohtomo K.
    Journal: Invest Radiol; 2009 Sep; 44(9):503-8. PubMed ID: 19652616.
    Abstract:
    PURPOSE: To investigate the feasibility of dynamic susceptibility-weighted contrast material-enhanced (DSC) perfusion imaging with ferucarbotran at 3.0 T, and to assess the impact of the different characteristics of gadolinium (Gd)- and ferucarbotran-based agent in rCBV measurement under pathologic condition with BBB disruption. MATERIALS AND METHODS: Nine patients with suspected meningioma (4 men and 5 women; age range, 27-79 years; mean age, 61.6 +/- 17.9 years) were eligible for the study. Approval was obtained from the institutional review board. All participants provided signed informed consent prior to the study. DSC perfusion images were acquired with a T2*-weighted echo-planar imaging sequence during the first pass of a standard-dose of Gd-based agent, and of 4, 8, or 16 micromol Fe/kg of ferucarbotran-based agent in 3 patients for each dose respectively. Pre- and postenhanced T1-weighted images were obtained in all. RESULTS: Ferucarbotran decreased the signal intensity in both gray and white matter in a dose-dependent fashion. Differences regarding the DeltaSI between the 4 and 8 or 8 and 16 micromol Fe/kg groups were statistically significant (P < 0.05, 1-way analysis of variance, Tukey-Kramer method) in any region. No effect of leakage of ferucarbotran was demonstrated in the intensity-time curves or in the postenhanced T1-weighted images. Relative CBV in tumor area obtained with Gd was reduced to 37.6%-86.5% compared with that obtained with ferucarbotran. CONCLUSIONS: T2*-weighted DSC perfusion imaging with ferucarbotran is feasible at 3.0 T. Compared with Gd-based agent, larger particle size of ferucarbotran can diminish the effect of contrast leakage during the first pass under pathologic conditions with BBB disruption.
    [Abstract] [Full Text] [Related] [New Search]